Juvenile Idiopathic Arthritis

Approximately 30% of patients with juvenile idiopathic arthritis develop temporomandibular joint involvement before transitioning to adult care, according to data published in Arthritis & Rheumatology.

Patients with juvenile idiopathic arthritis who demonstrate female sex, antinuclear antibody positivity and a positive family history have a higher risk for autoimmune thyroid disease, according to data published in Pediatric Rheumatology.

The FDA has approved a citrate-free, high-concentration formulation of the adalimumab biosimilar Hyrimoz, according to a press release from the manufacturer.

SCOTTSDALE, Ariz. — The prevalence of systematic-onset juvenile idiopathic arthritis-related lung disease appears to be on the rise, and being aware of clinical manifestations is important for catching the disease early, a speaker said.

Patients with juvenile idiopathic arthritis do not appear to have an increased risk for anxiety or depression, compared with the general population, according to data published in Pediatric Rheumatology.

Family history of autoimmune disease is a risk factor for developing of juvenile idiopathic arthritis, although it does not impact disease severity or course, according to data published in Pediatric Rheumatology.

Etanercept and adalimumab are both impactful at improving the health of patients with non-systemic juvenile idiopathic arthritis, according to data published in Pediatric Rheumatology.

In patients with juvenile idiopathic arthritis, genicular nerve block achieved “equivalent, longer-term improvement,” after 12 weeks compared with steroid therapy, according to data published in Clinical Rheumatology.

Patients with juvenile idiopathic arthritis who undergo therapy with TNF inhibitors have an outsized risk for later developing psoriasis, and other revelations, led Healio’s coverage of juvenile arthritis in 2022.

PHILADELPHIA — Patients with juvenile idiopathic arthritis started on conventional synthetic and biologic disease-modifying antirheumatic drug therapy concurrently had better results than patients on other plans, according to data presented here.